HIGHLIGHTS
- who: Rui Kitadai and Yusuke Okuma from the Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan have published the research: Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis, in the Journal: Cancers 2022, 2519 of /2022/
- what: An open-label phase 3 study was conducted to compare osimertinib 4 of 18 with platinum-based chemotherapy in advanced T790M-positive NSCLC patients who exhibited disease progression after first-line EGFR-TKI therapy. The analysis showed an improved OS . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.